论文部分内容阅读
浙江海正药业股份有限公司(简称:海正药业),是由浙江海正集团有限公司、国投兴业有限公司、三龙投资(中国)有限公司、四川抗菌素工业研究所、上海医药工业研究院、中国药科大学、浙江省医药工业公司及第二军医大学朝晖制药厂等八家单位共同发起设立的股份有限公司.经国务院证券委发[1997]73号文同意发行境内上市外资股(B股).海正药业是一家专业从事药品生产经营的公司.其母公司浙江海正集团有限公司是由原浙江海门制药厂整体改组而成,自1956年建厂以来,公司一直致力于产品开发、产品结构的调整及技术改造,全体员工在全国人大代表,执业药师白骅总经理领导下,海正药业现已发展成为国家大型企业、国家定点的抗生素抗肿瘤生产基地、国家重点高新技术企业和重要的出口创汇企业,利润总额居全国医药行业50强第9位.
Zhejiang Hisun Pharmaceutical Co., Ltd. (referred to as: Hisun Pharmaceutical) is established by Zhejiang Hezheng Group Co., Ltd., Guotou Xingye Co., Ltd., Sanlong Investment (China) Co., Ltd., Sichuan Antimicrobial Industry Research Institute, and Shanghai Pharmaceutical Industry. Research institutes, China Pharmaceutical University, Zhejiang Pharmaceutical Industry Corporation and Second Military Medical University Zhaohui Pharmaceutical Co., Ltd. jointly initiated the establishment of a joint stock limited company. It was approved by the State Council Securities Commission [1997] No. 73 to issue domestically listed foreign shares. (B shares). Hisun Pharmaceutical is a company specializing in pharmaceutical production and operation. Its parent company, Zhejiang Hisun Group Co., Ltd. was reorganized from the original Zhejiang Haimen Pharmaceutical Factory. Since the establishment of the factory in 1956, the company has been working hard. In the product development, product structure adjustment and technical transformation, under the leadership of the general manager of the NPC deputy and licensed pharmacist Bai Yu, Hisun Pharmaceutical has now developed into a national large-scale enterprise, national anti-tumor antibiotic production base, and national Key high-tech enterprises and important export-oriented foreign exchange enterprises, total profit ranks 9th among the top 50 pharmaceutical companies in the country.